149 related articles for article (PubMed ID: 11675522)
1. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients.
Calhoun EA; Chang CH; Welshman EE; Fishman DA; Lurain JR; Bennett CL
Oncologist; 2001; 6(5):441-5. PubMed ID: 11675522
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.
Bennett CL; Calhoun EA
Oncologist; 2007 Apr; 12(4):478-83. PubMed ID: 17470690
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of haematological adverse effects in cancer patients: a systematic review.
Liou SY; Stephens JM; Carpiuc KT; Feng W; Botteman MF; Hay JW
Clin Drug Investig; 2007; 27(6):381-96. PubMed ID: 17506589
[TBL] [Abstract][Full Text] [Related]
4. Costs associated with febrile neutropenia in the US.
Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
[TBL] [Abstract][Full Text] [Related]
6. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy.
Cosler LE; Calhoun EA; Agboola O; Lyman GH
Pharmacotherapy; 2004 Apr; 24(4):488-94. PubMed ID: 15098803
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
Gordon AN; Stringer CA; Matthews CM; Willis DL; Nemunaitis J
J Clin Oncol; 1997 May; 15(5):1965-73. PubMed ID: 9164208
[TBL] [Abstract][Full Text] [Related]
8. Resource implications of palliative chemotherapy for ovarian cancer.
Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
[TBL] [Abstract][Full Text] [Related]
9. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors.
Elting LS; Cantor SB; Martin CG; Hamblin L; Kurtin D; Rivera E; Vadhan-Raj S; Benjamin RS
Cancer; 2003 Mar; 97(6):1541-50. PubMed ID: 12627519
[TBL] [Abstract][Full Text] [Related]
10. The direct and indirect costs of Dravet Syndrome.
Whittington MD; Knupp KG; Vanderveen G; Kim C; Gammaitoni A; Campbell JD
Epilepsy Behav; 2018 Mar; 80():109-113. PubMed ID: 29414539
[TBL] [Abstract][Full Text] [Related]
11. Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers.
Yoshikawa T; Takano M; Miyamoto M; Yajima I; Shimizu Y; Aizawa Y; Suguchi Y; Moriiwa M; Aoyama T; Soyama H; Goto T; Hirata J; Suzuki A; Sasa H; Nagaoka I; Tsuda H; Furuya K
Cancer Chemother Pharmacol; 2017 Sep; 80(3):555-561. PubMed ID: 28726081
[TBL] [Abstract][Full Text] [Related]
12. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
13. Contribution of age to clinical trial enrollment and tolerance with ovarian cancer.
Gillen J; Gunderson C; Greenwade M; Rowland M; Ruskin R; Ding K; Crim A; Walter A; White E; Moore K
Gynecol Oncol; 2017 Apr; 145(1):32-36. PubMed ID: 28087143
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
[TBL] [Abstract][Full Text] [Related]
15. The Indirect Cost Burden of Cancer Care in Canada: A Systematic Literature Review.
Iragorri N; de Oliveira C; Fitzgerald N; Essue B
Appl Health Econ Health Policy; 2021 May; 19(3):325-341. PubMed ID: 33368032
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial.
Seagle BL; Shahabi S
Gynecol Oncol; 2017 Apr; 145(1):9-14. PubMed ID: 28196674
[TBL] [Abstract][Full Text] [Related]
17. Comparison of actual hospital costs versus DRG revenues for in-patient treatment of febrile neutropenia during adjuvant anthracycline plus/minus taxane-based chemotherapy for primary breast cancer.
Jacobs VR; Mayer SC; Paessens BJ; Bernard R; Harbeck N; Kiechle M; Ihbe-Heffinger A
Onkologie; 2011; 34(11):614-8. PubMed ID: 22104158
[TBL] [Abstract][Full Text] [Related]
18. Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia.
Bouwmans C; Janssen J; Huijgens P; Uyl-de Groot C
J Med Econ; 2009 Jun; 12(2):164-9. PubMed ID: 19606951
[TBL] [Abstract][Full Text] [Related]
19. Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial.
Hendricks AM; Loggers ET; Talcott JA
J Clin Oncol; 2011 Oct; 29(30):3984-9. PubMed ID: 21931037
[TBL] [Abstract][Full Text] [Related]
20. Neutropenic infections add significant costs to palliative chemotherapy in breast cancer.
Korpela J; Salminen E
Anticancer Res; 2002; 22(2B):1337-40. PubMed ID: 12168947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
